New York, United States, September 7, 2022 (GLOBE NEWSWIRE) — Chemiluminescence Immunoassay (CLIA) is an immunological technique for the detection and monitoring of chronic diseases. The diagnostic testing technique is performed in a CLIA analyzer. These chemiluminescent immunoassays (CLIA) find extensive application in the clinical diagnosis of various diseases, such as hereditary diseases, infectious diseases and cardiovascular diseases, among others.
Get a free sample copy of this report @ https://straitsresearch.com/report/chemiluminescence-immunoassay-market/request-sample
Chemiluminescence Immunoassay Market Drivers
The global market is driven by a number of factors such as: B. Increasing product innovation and the development of CLIA systems by market participants, the integration of technological advances to meet the growing diagnostic needs of chronic diseases, and the increasing demand for such diagnostic techniques to meet the growing diseased world population. For example, according to the American Diabetes Association, around 34.2 million people in the United States had diabetes in 2018, accounting for 10.5% of the country’s population.
In addition, the pandemic caused by the novel coronavirus is expected to increase the demand for novel chemiluminescent immunoassays Solutions for diagnostics and testing purposes. The huge patient pool and growing number of suspects being tested worldwide has created multiple opportunities in the market. For example, according to data reported to the WHO, as of December 8, 2020, there were 66.72 million confirmed cases of COVID-19, out of which 1.53 million deaths were reported.
In addition, business decisions, strategic collaborations, agreements, mergers and partnerships have positively impacted the market growth. For example, Abbott Laboratories signed and closed a $252.0 million contract with North West London Pathology (NWLP) to build a supply chain for…
